Chromocell Therapeutics (CHRO) Competitors $0.99 -0.04 (-3.88%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$0.99 0.00 (0.00%) As of 04:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock CHRO vs. CVKD, DARE, GBIO, SRZN, GDTC, OKUR, ALXO, ABVC, BCAB, and EGRXShould you be buying Chromocell Therapeutics stock or one of its competitors? The main competitors of Chromocell Therapeutics include Cadrenal Therapeutics (CVKD), Daré Bioscience (DARE), Generation Bio (GBIO), Surrozen (SRZN), CytoMed Therapeutics (GDTC), OnKure Therapeutics (OKUR), ALX Oncology (ALXO), ABVC BioPharma (ABVC), BioAtla (BCAB), and Eagle Pharmaceuticals (EGRX). These companies are all part of the "pharmaceutical products" industry. Chromocell Therapeutics vs. Cadrenal Therapeutics Daré Bioscience Generation Bio Surrozen CytoMed Therapeutics OnKure Therapeutics ALX Oncology ABVC BioPharma BioAtla Eagle Pharmaceuticals Chromocell Therapeutics (NYSE:CHRO) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations, media sentiment and community ranking. Which has more risk and volatility, CHRO or CVKD? Chromocell Therapeutics has a beta of 4.59, meaning that its share price is 359% more volatile than the S&P 500. Comparatively, Cadrenal Therapeutics has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500. Which has better earnings & valuation, CHRO or CVKD? Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than Chromocell Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChromocell TherapeuticsN/AN/A-$7.38M-$1.24-0.80Cadrenal TherapeuticsN/AN/A-$8.36M-$9.26-1.70 Do insiders and institutionals hold more shares of CHRO or CVKD? 78.0% of Chromocell Therapeutics shares are held by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are held by institutional investors. 16.4% of Chromocell Therapeutics shares are held by company insiders. Comparatively, 48.6% of Cadrenal Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media refer more to CHRO or CVKD? In the previous week, Cadrenal Therapeutics had 4 more articles in the media than Chromocell Therapeutics. MarketBeat recorded 4 mentions for Cadrenal Therapeutics and 0 mentions for Chromocell Therapeutics. Chromocell Therapeutics' average media sentiment score of 0.00 equaled Cadrenal Therapeutics'average media sentiment score. Company Overall Sentiment Chromocell Therapeutics Neutral Cadrenal Therapeutics Neutral Does the MarketBeat Community believe in CHRO or CVKD? Cadrenal Therapeutics received 6 more outperform votes than Chromocell Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformChromocell TherapeuticsOutperform Votes1100.00% Underperform VotesNo VotesCadrenal TherapeuticsOutperform Votes7100.00% Underperform VotesNo Votes Is CHRO or CVKD more profitable? Chromocell Therapeutics' return on equity of 0.00% beat Cadrenal Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Chromocell TherapeuticsN/A N/A -453.90% Cadrenal Therapeutics N/A -142.95%-118.40% Do analysts rate CHRO or CVKD? Cadrenal Therapeutics has a consensus price target of $32.00, suggesting a potential upside of 103.82%. Given Cadrenal Therapeutics' higher possible upside, analysts clearly believe Cadrenal Therapeutics is more favorable than Chromocell Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chromocell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Cadrenal Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryChromocell Therapeutics beats Cadrenal Therapeutics on 6 of the 11 factors compared between the two stocks. Get Chromocell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CHRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CHRO vs. The Competition Export to ExcelMetricChromocell TherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$6.53M$2.93B$5.37B$19.41BDividend YieldN/A1.72%5.22%3.83%P/E Ratio-0.8030.5026.7734.23Price / SalesN/A400.15393.1734.85Price / CashN/A168.6838.2517.51Price / Book-0.603.286.794.69Net Income-$7.38M-$72.17M$3.23B$1.02B7 Day Performance3.13%2.96%1.53%-1.74%1 Month Performance-36.13%3.25%10.06%7.46%1 Year Performance-40.36%-28.29%16.74%3.96% Chromocell Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CHROChromocell TherapeuticsN/A$0.99-3.9%N/A-46.8%$6.53MN/A-0.804Gap DownCVKDCadrenal Therapeutics2.5258 of 5 stars$13.75+2.8%$32.00+132.7%N/A$26.68MN/A-2.064DAREDaré Bioscience1.3921 of 5 stars$2.91+1.0%$24.00+724.7%-43.3%$25.75M$9,784.00-4.9330GBIOGeneration Bio3.2679 of 5 stars$0.38-1.6%$7.33+1,809.7%-88.4%$25.73M$19.89M-0.18150Negative NewsSRZNSurrozen2.9896 of 5 stars$7.77-2.9%$38.50+395.5%-24.7%$25.49M$10.66M-0.3180Gap DownGDTCCytoMed Therapeutics1.5935 of 5 stars$2.32+4.7%$5.00+115.1%+2.9%$25.43M$69,501.000.00N/AGap UpOKUROnKure Therapeutics2.9271 of 5 stars$1.82-6.9%$32.33+1,681.5%N/A$25.13MN/A-0.15N/AInsider TradeGap DownALXOALX Oncology3.2288 of 5 stars$0.47+6.8%$3.54+661.3%-97.0%$24.94MN/A-0.1640Analyst ForecastABVCABVC BioPharma0.1955 of 5 stars$1.48+8.5%N/A+10.2%$24.74M$508,384.00-1.7230Gap DownBCABBioAtla2.0058 of 5 stars$0.42-3.3%$6.00+1,335.4%-83.6%$24.41M$11M-0.2560Gap DownEGRXEagle PharmaceuticalsN/A$1.88-5.8%N/A-62.2%$24.35M$257.55M0.00100Gap Down Related Companies and Tools Related Companies Cadrenal Therapeutics Competitors Daré Bioscience Competitors Generation Bio Competitors Surrozen Competitors CytoMed Therapeutics Competitors OnKure Therapeutics Competitors ALX Oncology Competitors ABVC BioPharma Competitors BioAtla Competitors Eagle Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CHRO) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredHow I profit during chaos…This Guy THRIVES on Chaos Wall Street legend Larry Benedict has thrived through every major market crash. I...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chromocell Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chromocell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
